Skip to Content
How to talk to a doctor about advanced ovarian cancer >>

Lexiscan (regadenoson) Disease Interactions

There are 6 disease interactions with Lexiscan (regadenoson):

Major

Regadenoson (Includes Lexiscan) ↔ Mi

Severe Potential Hazard, Moderate plausibility

Applies to: Ischemic Heart Disease

The use of regadenoson has been associated with fatal and nonfatal myocardial infarction, ventricular arrhythmias, and cardiac arrest. Therapy with regadenoson should be avoided in patients with symptoms or signs of acute myocardial ischemia, such as unstable angina or cardiovascular instability as these patients may be at greater risk of serious cardiovascular reactions. Appropriate monitoring and equipment for resuscitation should be available before administering regadenoson. If serious reactions to regadenoson occur, consider the use of aminophylline, an adenosine antagonist, to shorten the duration of increased coronary blood flow induced by regadenoson administration.

Major

Regadenoson (Includes Lexiscan) ↔ Sinus/Av Node Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Sinus Node Dysfunction, Heart Block

The use of regadenoson is contraindicated in patients with second- or third- degree AV block, or with sinus node dysfunction in the absence of a functional artificial pacemaker. Adenosine receptor agonists, including regadenoson, can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia requiring intervention.

Moderate

Regadenoson (Includes Lexiscan) ↔ Arrhythmias

Moderate Potential Hazard, Moderate plausibility

Applies to: Arrhythmias

New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter, and cardiac arrest have occurred following regadenoson injection. Therapy with regadenoson should be administered cautiously in patients with cardiac conduction disorders.

Moderate

Regadenoson (Includes Lexiscan) ↔ Copd/Asthma

Moderate Potential Hazard, Moderate plausibility

Applies to: Asthma, Chronic Obstructive Pulmonary Disease

The use of regadenoson, as others adenosine receptor agonist may induce dyspnea, bronchoconstriction and respiratory compromise in patients with COPD or asthma. Appropriate bronchodilator therapy and resuscitative measures should be available prior to regadenoson administration.

Moderate

Regadenoson (Includes Lexiscan) ↔ Hypotension

Moderate Potential Hazard, Moderate plausibility

Applies to: Valvular Heart Disease, Pericarditis, Cerebrovascular Insufficiency

The use of adenosine receptor agonists, including regadenoson, has been associated with arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency.

Moderate

Regadenoson (Includes Lexiscan) ↔ Seizures

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures

The use of regadenoson may lower the seizure threshold. New-onset or recurrence of convulsive seizures has occurred following regadenoson injection. Caution is recommended when using this agent in patients with or predisposition to seizure disorders.

Lexiscan (regadenoson) drug Interactions

There are 49 drug interactions with Lexiscan (regadenoson)

Lexiscan (regadenoson) alcohol/food Interactions

There are 2 alcohol/food interactions with Lexiscan (regadenoson)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide